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Mitochondria are cellular organelles crucial for energy supply and calcium homeostasis in neuronal cells, and their
dysfunction causes seizure activity in some rare human epilepsies. To directly test whether mitochondrial respiratory
chain enzymes are abnormal in the most common form of chronic epilepsy, temporal lobe epilepsy (TLE), living human
brain specimens from 57 epileptic patients and 2 nonepileptic controls were investigated. In TLE patients with a hip-
pocampal epileptic focus, we demonstrated a specific deficiency of complex I of the mitochondrial respiratory chain in
the hippocampal CA3 region. In contrast, TLE patients with a parahippocampal epileptic focus showed reduced complex
I activity only in parahippocampal tissue. Inhibitor titrations of the maximal respiration rate of intact human brain slices
revealed that the observed reduction in complex I activity is sufficient to affect the adenosine triphosphate production
rate. The abnormal complex I activity in the hippocampal CA3 region was paralleled by increased succinate dehydro-
genase staining of neurons and marked ultrastructural abnormalities of mitochondria. Therefore, mitochondrial dysfunc-
tion is suggested to be specific for the epileptic focus and may constitute a pathomechanism contributing to altered
excitability and selective neuronal vulnerability in TLE.
Kunz WS, Kudin AP, Vielhaber S, Blu ¨mcke I, Zuschratter W, Schramm J, Beck H, Elger CE. Mitochondrial
complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy. Ann Neurol 2000;48:766–773
Human temporal lobe epilepsy (TLE) is a common
devastating neurological disorder characterized by re-
current seizures and selective vulnerability of hip-
pocampal neurons in specific hippocampal subfields.
1
Adequate energy supply by mitochondrial oxidative
phosphorylation is essential for neuronal excitability
and neuronal survival. Nevertheless, it is completely
unknown whether disturbed mitochondrial function
contributes to the pathophysiology of TLE. The im-
portance of mitochondria for neuronal excitability is
underscored by rare epilepsy syndromes in which
isolated mutations in mitochondrial transfer RNA
(tRNA) cause seizures. For instance, progressive myoc-
lonus epilepsy with “ragged red fibers” is caused by
point mutations in the mitochondrial tRNA
Lys.
2 Simi-
larly, the seizure activity seen in mitochondrial encepha-
lomyopathy with lactic acidosis and stroke-like episodes
is attributed to the impaired biosynthesis of mitochon-
drially encoded proteins of the respiratory chain due to a
mutation in the mitochondrial tRNA
Leu(UUR),
3 and a
mitochondrial tRNA
Ser(UCN) mutation was recently ob-
served in a patient with epilepsia partialis continua.
4
Moreover, mitochondrial toxins like 3-nitropropionic
acid or aminoxyacetic acid evoke seizures in mice.
5 In
addition, mitochondrial failure is an integral step in the
induction of neuronal cell death.
6
In this report, we have taken advantage of the
unique opportunity to investigate intact human brain
tissue from patients with therapy-refractory TLE to as-
sess directly possible alterations in mitochondrial func-
tion applying biochemical micromethods.
7
Patients and Methods
Patients
A total of 57 patients (age range, 8–62 years; median age,
33 years) with therapy-resistant TLE who underwent epi-
lepsy surgery were included in this study. Two patients (61
and 39 years of age) with a nonepileptogenic tumor in the
mesiotemporal lobe (one oligoastrocytoma and one glioblas-
toma grade IV) were used as controls. Because of the limi-
tation of available surgical tissue, all experiments were not
performed for each subject (see below). All epilepsy patients
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766 Copyright © 2000 by the American Neurological Associationwere classified into 2 distinct groups. One group (45 pa-
tients) showed severe segmental cell loss (approximate hip-
pocampal neuronal cell loss: 90% CA1, 70% CA3, 40%
dentate gyrus), mossy fiber sprouting, and gliosis within the
hippocampus but no evidence for extrahippocampal lesions
(Ammon’s horn sclerosis [AHS]). In those patients in whom
depth electrode recording was carried out (n 5 5) before
surgery, the seizure onset was invariably within the hip-
pocampus proper. The second group (12 patients) presented
without severe hippocampal pathology (approximate hip-
pocampal neuronal cell loss: 10% CA1, 5% CA3, 15% den-
tate gyrus; no mossy fiber sprouting). In 8 of these patients,
epileptogenic lesions were localized within the parahip-
pocampal gyrus (two gangliogliomas type I, one xanthoastro-
cytoma grade III, one cavernoma, and three pseudocystic le-
sions within the parahippocampal gyrus) or the amygdala
(n 5 1). The 4 remaining patients did not show neuro-
pathological abnormalities. In 3 of these patients, electroen-
cephalographic seizure onset was determined within the me-
sial temporal cortex but not the hippocampus proper. All
studies were approved by the University of Bonn Ethical
Committee.
Slice Preparation
Explanted hippocampal specimens were immediately placed
in ice-cold buffer containing 90 mM of NaCl, 3 mM of
KCl, 2 mM of MgSO4, 2 mM of CaCl2, 1 mM of sodium
pyruvate, 10 mM of glucose, 105 mM of sucrose, and
10 mM of 4-(2-hydroxyethyl)-1-piperazine-2-ethanesulfonic
acid (HEPES-NaOH; pH 7.4). Within 15 to 30 minutes
after surgery, 400-mm transverse sections were prepared with
a vibratome (Leica, Nussloch, Germany). The slices were mi-
crodissected, and the hippocampal subfields were transferred
to a holding chamber, pre-equilibrated for 60 minutes, and
stored until measurement at 25°C up to a maximum of 5
hours in a standard carbogen-gassed Ringer’s solution con-
taining 10 mM of glucose.
Enzyme Activities
The enzymatic analysis was carried out in 15 TLE patients
with AHS, 5 patients with lesion-associated TLE, and 2 non-
epileptic tumor patients. The activities of rotenone-sensitive
NADH:CoQ1 oxidoreductase and cytochrome c oxidase were
measured spectrophotometrically as previously described.
8
The activity of citrate synthase was determined by a standard
method.
9
Slice Respiration Measurements
Oxygen consumption measurements were performed using
single slices from all patients included in this study at 30°C
in a medium consisting of 125 mM of NaCl, 3 mM of KCl,
2 mM of CaCl2, 1.25 mM of sodium phosphate, 2 mM of
MgCl2, and 20 mM of HEPES-NaOH (pH 7.4) with a per-
sonal computer–supported high-resolution oxygraph.
7 The
sensitivity of the uncoupled pyruvate oxidation rate to 400
mM of fluorocitrate was determined in slices from 6 addi-
tional AHS patients (age range, 17–42 years).
Fig 1. Mitochondrial enzyme activities in
human hippocampal subfields and parahip-
pocampal gyrus. Citrate synthase normalized
activities of NADH:CoQ1 oxidoreductase (A)
and cytochrome c oxidase (B) in hippocampal
subfields and the parahippocampal gyrus of
Ammon’s horn sclerosis (AHS) (n 5 15),
parahippocampal lesions (n 5 5), and non-
epileptic control patients (n 5 2). Up/down
hatched bars 5 CA1 subfield; black bars 5
CA3 subfield; down/up hatched bars 5 den-
tate gyrus; white bars 5 parahippocampal
gyrus. *Statistically significant differences be-
tween the AHS and lesion groups (p ,
0.05).
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The histochemical and ultrastructural analysis was carried
out in hippocampal specimens of 13 TLE patients with
AHS, 6 patients with lesion-associated TLE, and 1 nonepileptic
tumor patient. Succinate histochemistry was performed by
standard procedures on native 60-mm microslices. The proto-
cols for electron microscopy have been described previously.
10
Statistical Analysis
The results are presented as mean 6 SD. Significant changes
were assessed by Student’s t test (with p , 0.05 as the level
of significance).
Results
To determine whether mitochondrial dysfunction oc-
curs within epileptic foci, we have taken advantage of
the fact that patients with TLE are readily classified
into 2 groups based on the location of the epileptic
focus. In the first group of patients, a hippocampal fo-
cus with a characteristic hippocampal neuropathology
consisting of segmental cell loss in the CA1 and CA3
pyramidal subfields, gliosis, and axonal reorganization
was determined (AHS group). The other group of pa-
tients showed no hippocampal pathology but had an
epileptogenic focal lesion and a seizure onset zone in
the parahippocampal gyrus (lesion group). From these
patients, we dissected the hippocampal subfields CA1
and CA3 and the dentate gyrus as well as the parahip-
pocampal gyrus within 30 minutes of epilepsy surgery.
This approach permitted us to assess which relation ex-
ists between the epileptic focus and the mitochondrial
function. We measured activities of two key enzymes
of the mitochondrial respiratory chain, rotenone-
sensitive NADH:CoQ1 oxidoreductase (complex I) and
cytochrome c oxidase (complex IV). Because reduced
numbers of mitochondria may influence these results
due to cell loss, we normalized the activities to the ac-
tivity of the mitochondrial marker enzyme citrate syn-
thase. As shown in Figure 1A, the normalized complex
I activities were substantially lower in the CA3 hip-
pocampal subfield in the AHS group (n 5 15) com-
pared with the lesion group (n 5 5; p , 0.05). Con-
versely, normalized complex I activities were
diminished in the parahippocampal gyrus but not in
the hippocampus of the lesion group. In contrast to
NADH:CoQ1 oxidoreductase activity, normalized ac-
tivities of cytochrome c oxidase were similar in all in-
vestigated brain areas (see Fig 1B). Thus, we directly
show a specific loss of complex I activity but not of
complex IV activity, which occurs exclusively within
the identified epileptic focus. This was the hippocam-
pal CA3 region in the AHS group and the parahip-
pocampal gyrus in the lesion group. In patients with-
out epilepsy, equal activity ratios of complex I and
complex IV were detected in all investigated brain areas
(see Fig 1A and B).
To determine the effect of these local complex I de-
ficiencies in epileptic patients on mitochondrial energy
supply, we measured the oxygen consumption of intact
human brain microslices applying high-resolution re-
spirometry,
7 and we subsequently applied increasing
concentrations of the specific inhibitors of complex I
Fig 2. Amytal titration curves of uncoupled pyruvate-oxidizing
hippocampal subfield slices and Dixon linearization of amytal
titration of NADH:CoQ1 oxidoreductase activity (insets). (A)
Ammon’s horn sclerosis patient. (B) Lesion patient. Open dia-
monds 5 CA1 subfield; open circles 5 CA3 subfield; open
inverse triangles 5 dentate gyrus; open triangles 5 parahip-
pocampal gyrus. The filled curve represents the amytal sensi-
tivity of the NADH:CoQ1 oxidoreductase in the corresponding
tissue homogenate determined from the Dixon linearization
shown in the inset. Insets: Dixon linearization of amytal sensi-
tivity of NADH:CoQ1 oxidoreductase activity in human brain
homogenates. Filled circles 5 hippocampal homogenates; open
triangles 5 homogenates from parahippocampal gyrus. (A)
Kd 5 109 mM; (B) Kd 5 136 mM.
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plex IV (azide: concentration range, 0–0.3 mM). We
observed that the amytal sensitivity is selectively in-
creased in the CA3 region of patients with AHS (Fig
2A; circles). In contrast, patients in the lesion group
showed an increased amytal sensitivity in parahip-
pocampal tissue (see Fig 2B; triangles). Such regional
differences were not observed for the complex IV in-
hibitor azide (not shown). Thus, areas in which direct
enzyme measurements revealed loss of complex I activ-
ity also displayed increased complex I inhibitor sensi-
tivity. To exclude the possibility that the increased
amytal sensitivity of mitochondrial oxygen consump-
tion is due to a change in the amytal sensitivity of
complex I, we determined the inhibition kinetics of
complex I by amytal (see Fig 2A and B; insets). No
significant differences in the Kd values for amytal in
hippocampal or parahippocampal tissue were detected.
To compare the inhibitor sensitivity of the enzymatic
reaction with the inhibitor sensitivity of the total met-
abolic flux, we added the theoretical inhibition curve of
the enzyme (derived from Dixon linearization) to the
plots showing the inhibition of the respiration flux by
amytal (see Fig 2A and B; filled lines). Interestingly, the
titration points of the respiration flux of the CA3 re-
gion of the AHS patients (see Fig 2A; circles)o ro ft h e
parahippocampal region of the lesion patients (see Fig
2B; triangles) almost approached this curve. This indi-
cates that the threshold is reached when the complex I
deficiency affects the adenosine triphosphate produc-
tion rate in these samples.
11
Quantification of the metabolic effect of complex I
deficiency in human brain specimens was performed by
metabolic control analysis
12–14 measuring the flux con-
trol coefficients of complexes I and IV in pyruvate-
oxidizing hippocampal subfields. We determined the
flux control coefficients from titration of the uncou-
pled pyruvate oxidation rate with the noncompetitive
inhibitors amytal and azide (Table). The complex I
flux control coefficients were significantly increased in
the CA3 region in the AHS group and in the parahip-
pocampal gyrus in the lesion group but were normal in
2 nonepileptic controls. In contrast to the abnormal
flux control coefficients determined for complex I, the
complex IV flux control coefficients showed no signif-
icant regional changes. Thus, flux control coefficients
are in line with the enzymatic data and indicate that
complex I deficiency affects the control of neuronal en-
ergy metabolism. It is important to note that these
changes in mitochondrial function could not be de-
tected in the CA1 subfield of patients with AHS. Here,
the maximal pyruvate oxidation rates were decreased by
approximately 25%, indicating a lower mitochondrial
quantity. Conversely, complex I:citrate synthase ratios
Table. Maximal Rates of Pyruvate-Supported Respiration and Flux Control Coefficients of Complexes I and IV of Respiratory
Chain in 400-mm Slices from Human Hippocampus
Subfield
Nonepileptic Controls
(n 5 2)
Ammon’s Horn Sclerosis
(n 5 45)
Lesion
(n 5 12)
CA1
Pyruvate oxidation rate 12.1 6 1.7 9.8 6 2.3 12.8 6 1.8
( p , 0.001
a)
Complex I flux control 0.26 6 0.005 0.25 6 0.09 0.31 6 0.07
Complex IV flux control 0.18 0.15 6 0.09 0.16 6 0.08
CA3
Pyruvate oxidation rate 13.8 6 1.3 13.4 6 4.3 14.7 6 3.3
Complex I flux control 0.23 6 0.05 0.39 6 0.12 0.21 6 0.09
( p , 0.001
a)
Complex IV flux control 0.19 0.21 6 0.12 0.13 6 0.05
Dentate gyrus
Pyruvate oxidation rate 13.2 6 2.1 13.5 6 3.2 13.7 6 2.9
Complex I flux control 0.28 6 0.01 0.25 6 0.09 0.25 6 0.07
Complex IV flux control 0.16 0.17 6 0.08 0.11 6 0.03
Parahippocampal gyrus
Pyruvate oxidation rate 13.3 6 1.9 12.1 6 2.6 12.6 6 2.1
Complex I flux control 0.24 6 0.01 0.25 6 0.10 0.34 6 0.08
( p , 0.05
a)
Complex IV flux control 0.19 0.20 6 0.07 0.14 6 0.07
The rates were determined at 30°C and expressed in nanomoles of O2 per minute per milligram of protein. The maximal slice respiration rates
were obtained in the presence of 10 mM of pyruvate and 3 mM of the uncoupler 4,5,6,7-tetrachloro-2-trifluoromethylbenzimidazole. The flux
control coefficients of complexes I and IV were determined from the initial slopes of amytal and azide titration experiments according to the
equation
14 Ci 52 (dJ/dI)/(Jmax/Kd), where Ci is the flux control coefficient, dJ/dI is the initial slope of the titration curve, Jmax is the
uninhibited respiration flux, and Kd is the dissociation constant of the inhibitors amytal (122 6 26 mM[ n5 12]) and azide (64 mM),
respectively.
14
aSignificance tested between Ammon’s horn sclerosis and parahippocampal lesion groups.
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(see Table) were normal. Because we observed an ap-
proximately 90% loss of pyramidal neurons in this re-
gion, the values may point to glial cells as the major
source for normal mitochondrial activity. This explana-
tion was substantiated by inhibition studies with fluo-
rocitrate, a selective inhibitor of aconitase in glial
cells.
15 In AHS patients, 400 mM of fluorocitrate in-
hibited the pyruvate oxidation rate in CA1 by 43 6
8%, although in the dentate gyrus, an area with less
severe neuronal cell loss, pyruvate oxidation was inhib-
ited only by 32 6 11% (n 5 6; p , 0.05), which is
similar to results in the CA3 subfield (35 6 9%) and
the parahippocampal gyrus (34 6 11%). The higher
fluorocitrate sensitivity of the sclerotic CA1 indicates a
larger glial contribution.
To pinpoint the regional and cellular localization of
abnormal mitochondria, we applied succinate dehydro-
genase (SDH) histochemistry. In contrast to the lesion
group (Figs 3A and 4A), patients with AHS exhibit
Fig 3. Succinate dehydrogenase
(SDH) histochemistry of the hip-
pocampus of a patient with a para-
hippocampal lesion (A) and a pa-
tient with Ammon’s horn sclerosis
(AHS) (B). In contrast to the lesion
(A), increased staining for SDH is
observed in the AHS sample (B) in
the CA3 pyramidal cell layer, al-
though this activity is almost missing
in the CA1 subfield. Bar 5 1 mm.
770 Annals of Neurology Vol 48 No 5 November 2000intense staining of neuronal cell somata within the
CA3 segment (see Figs 3B and 4B), indicating that ab-
normal mitochondria are located within the cell soma
of surviving CA3 pyramidal cells. This may reflect
an adaptational response to the mitochondrial defect
known to occur in mitochondrial DNA diseases.
2 Fur-
thermore, we examined mitochondrial morphology by
electron microscopy. Diminished complex I activities
in the CA3 region of AHS patients were accompanied
by severe ultrastructural abnormalities of mitochondria
in the CA3 pyramidal cells (see Fig 4D). Swollen mi-
tochondria with a rarefied or irregular cristae structure
(see Fig 4D; arrow) were frequently observed in AHS
patients but not in TLE patients with focal lesions (see
Fig 4C) or nonepilepsy controls (not shown). It should
be noted, however, that not all mitochondria of the
CA3 pyramidal cells from AHS patients showed an ab-
normal morphology (see Fig 4D), which is characteris-
tic for mitochondrial pathologies and excludes fixation
artifacts.
Fig 4. Succinate dehydrogenase (SDH) staining (A and B) and electron microscopy (C and D) in the CA3 subfield of human hip-
pocampus. SDH histochemistry is seen in a parahippocampal lesion patient with faint reactivity (A) and in an Ammon’s horn scle-
rosis (AHS) patient with increased cellular staining (B). Bar 5 50 mm. (C) Ultrastructural analysis of somatic mitochondria in a
CA3 pyramidal cell of a lesion patient. Bar 5 1 mm. (D) In contrast, some mitochondria in AHS patients show severe structural
alterations (arrow), including swelling and rarefied cristae. Bar 5 0.8 mm.
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Our observation of local mitochondrial dysfunction in
vitro correlates well with regional abnormalities in en-
ergy metabolism in vivo, which are suggested by the
glucose hypometabolism
16 and decreased phosphocre-
atine:phosphate ratios
17 observed within the epileptic
focus of TLE patients. Our finding indicates novel
pathophysiological mechanisms important in human
TLE. First, mitochondria are involved in controlling
intracellular Ca
21, and the complex I deficiency could
lead to elevated cytosolic Ca
21 levels. This mechanism
is thought to be responsible for the multifocal seizure
activity seen in mitochondrial DNA diseases affecting
the activities of mitochondrially encoded enzymes of
the respiratory chain.
18 These disorders demonstrate
that isolated mitochondrial tRNA mutations can cause
seizures, strongly suggesting that the mitochondrial
dysfunction we show here may contribute to hyperex-
citability in TLE. A second intriguing possibility is that
the observed complex I deficiency could contribute to
the selective pyramidal cell death occurring in human
TLE. This notion is supported by the finding that the
respiratory chain function was abnormal within the
CA3 region of AHS patients, an area with significant
neuronal cell loss, but normal within the dentate gyrus,
which is usually well preserved. The mitochondrial
proliferation in CA3 neurons (indicated by the in-
creased SDH staining) is most likely responsible for the
observed normal pyruvate oxidation rates in this sub-
field. The normalized complex I:citrate synthase activ-
ity ratios, which do not depend on mitochondrial
quantity and therefore allow the detection of respira-
tory chain enzyme deficiencies,
8 were decreased, how-
ever. Conversely, the devastating loss of about 90% of
pyramidal neurons in CA1 (which is indicated by the
almost missing SDH staining; see Fig 3B) precludes
the accurate measurement of neuronal mitochondrial
enzyme activities. The normal complex I:citrate syn-
thase ratios at decreased pyruvate oxidation rates to-
gether with the increased fluorocitrate sensitivity sug-
gest that glial cells significantly contribute to
mitochondrial activity in the sclerotic CA1 region of
AHS patients.
It is improbable that the observed local deficiencies
of mitochondrial complex I are related to the medica-
tion of the patients, because both groups received sim-
ilar anticonvulsant therapy for at least 1 month before
surgery (carbamazepine monotherapy in 21 of 45 AHS
patients and 8 of 12 lesion-associated TLE patients,
carbamazepine and lamotrigin therapy in 12 of 45
AHS patients and 2 of 12 lesion-associated TLE pa-
tients, and valproate monotherapy in 9 of 45 AHS pa-
tients and 2 of 12 lesion-associated TLE patients; 3
AHS patients received a combined regimen of other
anticonvulsants).
The pivotal role of a complex I deficiency has also
been surmised in the loss of substantia nigra neurons in
Parkinson’s disease.
19 This concept may therefore facil-
itate the development of novel neuroprotective strate-
gies in the treatment of TLE. The feasibility of this
line of reasoning is underscored by the recent finding
that creatine administration, which causes buffering of
intracellular energy levels, rescues motor neurons in a
transgenic mouse model of motor neuron disease
20 and
suppresses seizures in hypoxic rat pups.
21 Thus, it may
become possible to prevent the progressive seizure-
associated cell loss in vulnerable regions in addition to
conventional anticonvulsant therapy.
In summary, we have, for the first time, directly
demonstrated a local impairment of mitochondrial
function in the epileptic focus of patients with TLE
that severely affects neuronal energy metabolism. We
propose that the observed complex I deficiency may be
important for enhanced excitability as well as for selec-
tive neuronal vulnerability in TLE, which may have
implications for new therapeutic strategies in the treat-
ment of this disease.
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